Icahn Reports No Shares Of Clorox, Vector Group, More Shares Of El Paso

Billionaire investor Carl Icahn reported in a regulatory filing on Tuesday that he no longer held a position in Clorox Co. (CLX), a company whose board he failed to unseat in an effort to force a sale of the company.

Icahn also reported no longer holding shares of Vector Group (VGR), which owns the prominent New York-area real estate brokerage Douglas Elliman Realty LLC and cigarette maker Liggett Group LLC.

The changes in Icahn's positions where revealed in a 13-F filing that is required by many investors who manage more than $100 million. Icahn's filing represents his holdings as of Dec. 31, 2011.

Around late November, Icahn reported in separate filing, that he had lowered his stakes in Clorox and in Vector Group each to 4.99% of shares. The move put him just under the 5% threshold that requires investors to report on sales or purchases of shares as the happen.

Meanwhile, Icahn reported his stake in energy company El Paso Corp. (EP) had risen 9.5% from the third quarter. As of Dec. 31, he owned 72.3 million shares of the company, or 9.4%.

In October, Kinder Morgan Inc. (KMI) agreed to buy El Paso Corp. and is now reportedly in talks with private equity firms to sell the company's oil-and-gas exploration and production unit.

According to the 13-F, the rest of Icahn's holdings remained largely unchanged from the previous quarter.

Since the end of the reported quarter, Icahn has been making waves at another company he invested in last month, CVR Energy (CVI). Icahn, who is pushing the petroleum refiner to sell itself, recently reported raising his stake in the company to 12.6 million shares--about 14.5% of the total outstanding shares and just under the CVR Energy's 15% poison pill.

Icahn said in a separate last week that CVR Energy 's stock price is undervalued, making it a viable sales candidate, and that he's considering nominating directors for CVR Energy's board.

He has also continued raising his shares of WebMD Health Corp. (WBMD) this year, reporting in January an 11.6% stake in the company.

-By Annie Gasparro, Dow Jones Newswires; 212-416-2244; [e-mail]